Command Palette

Search for a command to run...

shree-ganesh-remedies

497.25-0.60%
Market Cap
₹642.20 Cr
Stock P/E
29.37
ROCE
19.53%
ROE
17.26%
Book Value
₹115.75

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

POSITIVES
  • Volumetric growth was achieved despite top-line pressure in Q4 FY25.
  • Crams projects continued to contribute positively, helping sustain profitability.
NEGATIVES
  • Q4 FY25 revenue declined 35% year-on-year, signaling end-market weakness.
  • European slowdown and lower realizations in domestic portfolio pressured margins and demand.

Peers Summary

Sector Leader

Shree Ganesh Remedies Ltd. shows a mixed performance in the Pharmaceuticals sector, with some strong efficiency metrics but lacking growth and profitability compared to its peers. Companies like Dr. Reddy's Laboratories and Cipla emerge as strong overall performers due to their balanced growth, profitability, and attractive valuations, while Sun Pharmaceutical is notably overvalued relative to its performance.

Key Points
  • Shree Ganesh Remedies has a low revenue growth rate and no profit margin, which raises concerns about its competitiveness.
  • Dr. Reddy's Laboratories and Cipla are standout performers with strong profitability and good growth metrics.
  • Sun Pharmaceutical and Divi's Laboratories are considered overvalued given their high P/E ratios despite lower growth rates.
Top Performers
Dr. Reddy's Laboratories Ltd.

Best overall profitability with high ROE and low valuation metrics.

Cipla Ltd.

Strong growth coupled with attractive valuation ratios.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.